CS 5006
Alternative Names: CS-5006Latest Information Update: 16 Jul 2026
At a glance
- Originator CStone Pharmaceuticals
- Class Alkaloids; Antibodies; Antineoplastics; Bispecific antibodies; Camptothecins; Drug conjugates; Immunoconjugates
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 22 Apr 2026 Pharmacodynamics, pharmacokinetics and adverse events data from a preclinical studies in Solid tumours presented at the 117th Annual Meeting of the American Association for Cancer Research, 2026 (AACR-2026)
- 20 Apr 2026 Adverse events, pharmacodynamics and pharmacokinetics data from a preclinical trial in Solid tumours released by CStone Pharmaceuticals
- 19 Apr 2026 Pharmacodynamics and pharmacokinetic data from a preclinical trial in Solid tumours released by CStone Pharmaceuticals